Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?
Oncoscience
.
2015 Jun 5;2(6):567-9.
doi: 10.18632/oncoscience.168.
eCollection 2015.
Authors
Maria Rosa Cappelletti
1
,
Letizia Gnetti
2
,
Daniele Santini
3
,
Daniele Spada
1
,
Stephen B Fox
4
,
Daniele Generali
1
Affiliations
1
U.S. Terapia Molecolare e Farmacogenomica, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy.
2
Department of Onco-Haematological and Internal Medicine, Section of Pathology University of Parma, Parma, Italy.
3
University Campus Bio-Medico Roma, Oncologia Medica, Roma, Italy.
4
Department of Anatomical Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
PMID:
26244161
PMCID:
PMC4506357
DOI:
10.18632/oncoscience.168
No abstract available
Keywords:
FGFR inhibitors; FGFR2; endometrial cancer; everolimus.